Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, extension trial to evaluate the long-term safety and
efficacy of RPC1063 in patients with moderately to severely active ulcerative colitis (UC).
The purpose of this extension trial is to evaluate the long-term safety and efficacy of
RPC1063 in patients with moderately to severely active ulcerative colitis (UC).
Only those patients who have previously participated in a trial of RPC1063, being either
RPC01-3101 or completed at least 1 year of the open-label period of RPC01-202 will be
eligible